10-KPeriod: FY2012

PFIZER INC Annual Report, Year Ended Dec 31, 2012

Filed February 28, 2013For Securities:PFE

Summary

Pfizer Inc. is undergoing a significant strategic transformation, as evidenced by the recent IPO of its Animal Health business, Zoetis. This move, along with the divestiture of its Nutrition business to Nestlé and the sale of Capsugel, signals a clear focus on its core biopharmaceutical operations. The company is emphasizing its innovative core (Primary Care, Specialty Care, and Oncology) and its value core (Established Products), alongside a global Emerging Markets unit. Despite these strategic shifts, Pfizer faces considerable challenges, including patent expirations for key products like Lipitor and the increasing threat of generic competition. The company's R&D spending remains substantial, reflecting a commitment to innovation, but also highlighting the inherent risks and unpredictability of drug development. Investors should monitor the success of pipeline products and the company's ability to navigate the complex regulatory and pricing environments in both developed and emerging markets.

Financial Highlights

56 data points
Beta

Revenue

$54.66B

82.0% Gross Margin

Net Income

$14.57B

26.7% Net Margin

EPS (Diluted)

$1.94

Total Assets

$185.80B

Cash & Equivalents

$10.08B

Free Cash Flow

$15.42B

Financial Statements
Beta
Revenue$54.66B
Cost of Revenue$9.82B
Gross Profit$44.84B
SG&A Expenses$15.17B
Operating Income$8.99B
Interest Expense$1.52B
Net Income$14.57B
EPS (Basic)$1.96
EPS (Diluted)$1.94
Shares Outstanding (Basic)7.44B
Shares Outstanding (Diluted)7.51B

Key Highlights

  • 1Pfizer completed the IPO of its Animal Health subsidiary, Zoetis, in February 2013, marking a strategic shift towards its core biopharmaceutical business.
  • 2The company divested its Nutrition business to Nestlé for $11.85 billion in cash in November 2012, further streamlining its portfolio.
  • 3Biopharmaceutical revenues, while still dominant at 87% of total revenues in 2012, saw a 11% decrease compared to 2011, primarily due to loss of exclusivity for key products like Lipitor.
  • 4Significant R&D investment of $7.9 billion in 2012 underscores Pfizer's commitment to innovation, with 78 programs in Phase 1 through registration.
  • 5The company is strategically realigning its R&D focus to five high-priority areas: immunology and inflammation; oncology; cardiovascular and metabolic diseases; neuroscience and pain; and vaccines.
  • 6International operations represent a substantial portion of revenue, accounting for 61% in 2012, though these markets present unique regulatory and pricing challenges.
  • 7Pfizer is actively repurchasing shares, with approximately $135.98 million worth of shares purchased under announced plans in the fourth quarter of 2012.

Frequently Asked Questions

Pfizer is actively divesting non-core assets and focusing on its biopharmaceutical business. This includes the recent IPO of its Animal Health division (Zoetis) and the sale of its Nutrition business. The company is structuring its operations around an 'innovative core' (Primary Care, Specialty Care, Oncology) and a 'value core' (Established Products), alongside a focus on Emerging Markets.

The primary risks include the loss of exclusivity for key blockbuster drugs, leading to significant revenue decline due to generic competition (e.g., Lipitor). The company also faces pricing pressures from governments and managed care organizations globally, evolving regulatory landscapes (like the Affordable Care Act in the U.S.), and the inherent unpredictability and high cost of pharmaceutical research and development.

Pfizer is heavily investing in research and development to build a robust pipeline of new products and indications. The company is focusing its R&D efforts on five high-priority therapeutic areas and actively pursuing business development opportunities, including acquisitions and licensing, to offset revenue losses from products losing patent protection and to drive future growth.

In 2012, international operations accounted for 61% of Pfizer's total revenue, with the U.S. being the largest single market at 39%. Japan is the second-largest national market. International operations are subject to various risks, including currency fluctuations, differing regulatory environments, price controls, and political instability in some emerging markets.